Synlogic (SYBX) Investor Presentation - Slideshow

SYNB8802 Differentiation: Site of Action, Flexibility, Reversibility | --- | --- | |------------------|---------| | | | | Reversible | Current | | (non-colonizing) | Status | Pending POC data © 2023 SYNLOGIC. CORPORATE PRESENTATION. ALL RIGHTS RESERVED. | 43 LS mean change over Placebo, +/- 90% CI, all days baseline and treated. 1. Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery, American Society of Nephrology Kidney Week, Novem ...